CRBP

Corbus Pharmaceuticals Holdings, Inc. [CRBP] Stock Forecast

Q: What is Corbus Pharmaceuticals Holdings, Inc. stock symbol ?

Corbus Pharmaceuticals Holdings, Inc. is a US stock, located in Norwood of Ma and trading under the symbol CRBP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CRBP Stock Summary

CRBP has more than 4 years of cash runway (51 months)

Top 10 Correlated Stocks

CRBP

In the News

CRBP Financial details

Company Rating

Sell

Market Cap

428.64M

Income

-45.55M

Revenue

1.35M

Book val./share

-1.56

Cash/share

4.77

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 May 2024

P/E

-0.66

Forward P/E

PEG

0.32

P/S

P/B

102.69

P/C

7.92

P/FCF

-0.63

Quick Ratio

0.91

Current Ratio

0.99

Debt / Equity

-3.02

LT Debt / Equity

-0.47

EPS (TTM)

-10.6

EPS next Y

EPS next Q

EPS this Y

-23%

EPS next Y

EPS next 5Y

EPS last 5Y

-20.5%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-20.26%

SMA20

-4.88%

SMA50

56%

SMA100

875%

Inst Own

Inst Trans

ROA

-134%

ROE

-327%

ROC

-9.65%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

3.033-49.87

52W High

-22.86%

52W Low

+1160%

RSI

Rel Volume

0.06

Avg Volume

973.77K

Volume

55.83K

Perf Week

-5.5%

Perf Month

-15.87%

Perf Quarter

625.53%

Perf Half Y

527.91%

Beta

2.473

Volatility

2.35%, 2.99%

Prev Close

3.48%

Price

37.8

Change

4.51%

CRBP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	16.97	1.51	0.22	0	0
Net income per share	-32.47	-42.74	-11.11	-13.39	-10.31
Operating cash flow per share	-21.47	-38.28	-11.75	-9	-8.34
Free cash flow per share	-22.75	-38.46	-11.77	-9.01	-8.34
Cash per share	14.91	32.8	23.82	14.19	4.88
Book value per share	2.89	17.38	16.86	7.91	-1.6
Tangible book value per share	2.89	17.38	16.86	7.91	-1.6
Share holders equity per share	2.89	17.38	16.86	7.91	-1.6
Interest debt per share	4.44	9.91	-440.01	5.5	5.5
Market cap	348.89M	97.67M	75.76M	13.89M	26.14M
Enterprise value	326.59M	39.07M	77.35M	21.98M	33.11M
P/E ratio	-5.05	-0.88	-1.66	-0.25	-0.59
Price to sales ratio	9.65	24.81	85.93	0	0
POCF ratio	-7.63	-0.98	-1.57	-0.37	-0.72
PFCF ratio	-7.2	-0.98	-1.57	-0.37	-0.72
P/B Ratio	56.66	2.16	1.1	0.42	-3.79
PTB ratio	56.66	2.16	1.1	0.42	-3.79
EV to sales	9.04	9.92	87.72	0	0
Enterprise value over EBITDA	-4.24	-0.32	-1.37	-0.74	-0.75
EV to operating cash flow	-7.14	-0.39	-1.61	-0.59	-0.92
EV to free cash flow	-6.74	-0.39	-1.6	-0.59	-0.92
Earnings yield	-0.2	-1.14	-0.6	-4.02	-1.71
Free cash flow yield	-0.14	-1.03	-0.64	-2.7	-1.38
Debt to equity	1.53	0.59	0.38	0.76	-3.02
Debt to assets	0.19	0.26	0.25	0.38	0.74
Net debt to EBITDA	0.29	0.48	-0.03	-0.27	-0.16
Current ratio	1.09	2.89	5.89	4.76	0.74
Interest coverage	-4.05K	119.42	0.03	18.68	-15.42
Income quality	0.64	0.9	1.06	0.89	0.81
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.65	7.23	23.17	0	0
Research and developement to revenue	2.48	24.96	41.34	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.06	0	0	0	0
Capex to revenue	-0.08	-0.12	-0.06	0	0
Capex to depreciation	-2.23	-0.29	-0.03	-0.01	0
Stock based compensation to revenue	0.33	3.16	10.75	0	0
Graham number	45.96	129.29	64.92	48.81	19.24
ROIC	-3.07	-1.53	-0.54	-0.82	-2.62
Return on tangible assets	-1.41	-1.09	-0.42	-0.84	-1.58
Graham Net	-4.96	11.72	14.4	6.2	-3.25
Working capital	3.27M	60.18M	83.2M	47.54M	-8.35M
Tangible asset value	6.16M	45.27M	69.11M	32.99M	-6.9M
Net current asset value	-4.83M	35.05M	61.58M	26.86M	-11.63M
Invested capital	1.53	0.59	0.38	0.76	-3.02
Average receivables	1.34M	2.63M	1.29M	0	0
Average payables	8.72M	9.24M	4.58M	1.98M	2.68M
Average inventory	-1.34M	-1.17M	175K	0	0
Days sales outstanding	27.08	239.02	0	0	0
Days payables outstanding	45.18K	27.42K	396.85	533.32	1.81K
Days of inventory on hand	-10.92K	1.3K	0	0	0
Receivables turnover	13.48	1.53	0	0	0
Payables turnover	0.01	0.01	0.92	0.68	0.2
Inventory turnover	-0.03	0.28	0	0	0
ROE	-11.23	-2.46	-0.66	-1.69	6.46
Capex per share	-1.29	-0.19	-0.01	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0.31
Net income per share	-2.62	-4.47	-2.05	-2.27	-1.81
Operating cash flow per share	-1.79	-3.61	-1.82	-1.62	-1.36
Free cash flow per share	-5	-3.61	-1.82	-1.62	-1.36
Cash per share	14.19	10.58	8.55	6.5	4.77
Book value per share	7.91	3.94	2.23	0.07	-1.56
Tangible book value per share	7.91	3.94	2.23	0.07	-1.56
Share holders equity per share	7.91	3.94	2.23	0.07	-1.56
Interest debt per share	5.86	5.78	5.36	5.34	4.88
Market cap	13.89M	30.4M	33.54M	29.82M	26.72M
Enterprise value	21.98M	47.91M	48.91M	41.42M	33.69M
P/E ratio	-0.32	-0.41	-0.95	-0.74	-0.83
Price to sales ratio	0	0	0	0	19.8
POCF ratio	-1.86	-2.01	-4.3	-4.15	-4.45
PFCF ratio	-0.67	-2.01	-4.3	-4.15	-4.45
P/B Ratio	0.42	1.85	3.52	95.86	-3.87
PTB ratio	0.42	1.85	3.52	95.86	-3.87
EV to sales	0	0	0	0	24.96
Enterprise value over EBITDA	-1.98	-2.77	-6.09	-4.47	-3.38
EV to operating cash flow	-2.95	-3.17	-6.27	-5.77	-5.61
EV to free cash flow	-1.05	-3.17	-6.27	-5.77	-5.61
Earnings yield	-0.79	-0.61	-0.26	-0.34	-0.3
Free cash flow yield	-1.5	-0.5	-0.23	-0.24	-0.22
Debt to equity	0.76	1.51	2.49	73.49	-3.02
Debt to assets	0.38	0.48	0.54	0.63	0.74
Net debt to EBITDA	-0.73	-1.01	-1.91	-1.25	-0.7
Current ratio	4.76	3.19	2.34	0.99	0.74
Interest coverage	16.84	25.51	10.56	-12.43	-14.29
Income quality	0.69	0.85	0.89	0.71	0.75
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	2.31
Research and developement to revenue	0	0	0	0	5.17
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	1.8	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-35.87	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0.59
Graham number	21.61	19.89	10.14	1.9	7.98
ROIC	-0.17	-0.39	-0.23	-0.36	-0.59
Return on tangible assets	-0.17	-0.36	-0.2	-0.28	-0.28
Graham Net	6.2	2.16	0.55	-1.64	-3.18
Working capital	47.54M	31.51M	21.89M	-336.36K	-8.35M
Tangible asset value	32.99M	16.46M	9.52M	311.02K	-6.9M
Net current asset value	26.86M	10.68M	4.07M	-4.77M	-11.63M
Invested capital	0.76	1.51	2.49	73.49	-3.02
Average receivables	0	0	0	0	0
Average payables	1.77M	1.75M	1.41M	3.11M	3.95M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	522.84	327.35	855.84	2.78K	1.93K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.17	0.27	0.11	0.03	0.05
Inventory turnover	0	0	0	0	0
ROE	-0.33	-1.14	-0.92	-32.32	1.16
Capex per share	-3.22	0	0	0	0

CRBP Frequently Asked Questions

What is Corbus Pharmaceuticals Holdings, Inc. stock symbol ?

Corbus Pharmaceuticals Holdings, Inc. is a US stock , located in Norwood of Ma and trading under the symbol CRBP

What is Corbus Pharmaceuticals Holdings, Inc. stock quote today ?

Corbus Pharmaceuticals Holdings, Inc. stock price is $37.8 today.

Is Corbus Pharmaceuticals Holdings, Inc. stock public?

Yes, Corbus Pharmaceuticals Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 973.77K
Market Capitalization 428.64M
Employee 19
CEO Dr. Yuval Cohen Ph.D.
Headquarters Norwood,MA,US
IPO Date 2014-10-27
Website https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.